Past activities & Achievements    

Since inception of the programme in 2011, GALVmed has collaborated with more than 20 research partners comprising a global mix of private pharmaceutical companies, universities, and public research institutes to develop a better product for reducing the impact of this major African cattle disease. Collaborations have included the search for effective vaccines, development of a pen-side test, development of new classes of trypanocides and improved integrated control methods and better-quality control for drugs sold in Africa.

Overview and Objectives   

The focus of the AAT programme has been to identify and de-risk the development of a target molecule to generate information allowing a commercial partner to prepare a registration package and subsequently commercialise a safe and effective drug.

Over the lifetime of the project approximately 12,000 compounds have been assessed for safety, efficacy and cost.

Programme Activities    

GALVmed, in partnership with the Gates Foundation, FCDO and Boehringer Ingelheim, is conducting research and collaborating with other projects to create a new solution to AAT. This unique collaboration is the world’s only programme to develop a new, commercially available solution for AAT.